摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-hydroxy-7-(4-hydroxy-3,5-dimethylphenyl)-4-methoxy-1,6-naphthyridin-5(6H)-one | 924365-77-5

中文名称
——
中文别名
——
英文名称
2-hydroxy-7-(4-hydroxy-3,5-dimethylphenyl)-4-methoxy-1,6-naphthyridin-5(6H)-one
英文别名
7-(4-hydroxy-3,5-dimethylphenyl)-4-methoxy-1,6-dihydro-1,6-naphthyridine-2,5-dione
2-hydroxy-7-(4-hydroxy-3,5-dimethylphenyl)-4-methoxy-1,6-naphthyridin-5(6H)-one化学式
CAS
924365-77-5
化学式
C17H16N2O4
mdl
——
分子量
312.325
InChiKey
WGRLUDBFYJSWJG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    23
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    87.7
  • 氢给体数:
    3
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    2-hydroxy-7-(4-hydroxy-3,5-dimethylphenyl)-4-methoxy-1,6-naphthyridin-5(6H)-one盐酸 作用下, 以 乙醚 为溶剂, 反应 1.0h, 以37%的产率得到2-hydroxy-7-(4-hydroxy-3,5-dimethylphenyl)-4-methoxy-1,6-naphthyridin-5(6H)-one hydrochloride
    参考文献:
    名称:
    COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
    摘要:
    本公开涉及化合物,这些化合物可用于调节载脂蛋白A-I(ApoA-I)的表达,以及它们用于治疗和预防心血管疾病及相关疾病状态,包括胆固醇或脂质相关紊乱,例如,动脉粥样硬化。
    公开号:
    US20080188467A1
  • 作为产物:
    描述:
    7-(4-benzyloxy-3,5-dimethyl-phenyl)-2,4-dimethoxy-6H-[1,6]naphthyridin-5-one 在 三溴化硼 作用下, 以 二氯甲烷 为溶剂, 反应 16.0h, 生成 2-hydroxy-7-(4-hydroxy-3,5-dimethylphenyl)-4-methoxy-1,6-naphthyridin-5(6H)-one
    参考文献:
    名称:
    COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
    摘要:
    本公开涉及化合物,这些化合物可用于调节载脂蛋白A-I(ApoA-I)的表达,以及它们用于治疗和预防心血管疾病及相关疾病状态,包括胆固醇或脂质相关紊乱,例如,动脉粥样硬化。
    公开号:
    US20080188467A1
点击查看最新优质反应信息

文献信息

  • TREATMENT OF DISEASES BY EPIGENETIC REGULATION
    申请人:McLure Kevin G.
    公开号:US20130281397A1
    公开(公告)日:2013-10-24
    The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma; autoimmune or inflammatory diseases or conditions, and sepsis.
    本公开提供了抑制结构域和额外末端结构域(BET)蛋白的非天然存在的多化合物。所公开的组合物和方法可用于治疗和预防癌症,包括NUT中线癌、Burkitt淋巴瘤、急性髓系白血病和多发性骨髓瘤;自身免疫或炎症性疾病或症状,以及败血症。
  • Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices
    申请人:Wong Norman C.W.
    公开号:US20090029987A1
    公开(公告)日:2009-01-29
    The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.
    本发明涉及一种类似于多化合物,可用于抑制哺乳动物中VCAM-1表达、MCP-1表达和/或SMC增殖。所披露的化合物可用于调节炎症状态的标志物,包括血管炎症,并用于治疗和预防炎症和心血管疾病及相关疾病状态。
  • Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
    申请人:Wong Norman C. W.
    公开号:US08410109B2
    公开(公告)日:2013-04-02
    The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.
    本发明涉及一种类似多的化合物,可用于抑制哺乳动物中VCAM-1表达、MCP-1表达和/或SMC增殖。所述化合物可用于调节炎症状况的标志物,包括血管炎症,并用于治疗和预防炎症和心血管疾病及相关疾病状态。
  • US8053440B2
    申请人:——
    公开号:US8053440B2
    公开(公告)日:2011-11-08
  • US8410109B2
    申请人:——
    公开号:US8410109B2
    公开(公告)日:2013-04-02
查看更多